Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Exelixis Inc (NQ: EXEL )

22.43 +0.49 (+2.23%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 4, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,032,287
Open 21.84
Bid (Size) 21.88 (2)
Ask (Size) 22.50 (5)
Prev. Close 21.94
Today's Range 21.81 - 22.44
52wk Range 15.32 - 22.80
Shares Outstanding 315,048,788
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Exelixis Announces Initiation of the STELLAR-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck Cancer
From Exelixis, Inc.
Via Business Wire
Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma
From Arcus Biosciences
Via Business Wire

Performance

YTD
+37.61%
+37.61%
1 Month
+7.63%
+7.63%
3 Month
+0.72%
+0.72%
6 Month
+15.14%
+15.14%
1 Year
+30.26%
+30.26%

More News

Read More
Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment
Via FinancialNewsMedia
Topics Death
Exposures Death
NASDAQ:EXEL, a growth stock which is not overvalued.
Via Chartmill
Looking for growth without the hefty price tag? Consider NASDAQ:EXEL.
Via Chartmill
Exelixis to Present at the Piper Sandler 35th Annual Healthcare Conference on November 28, 2023
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023
From Exelixis, Inc.
Via Business Wire
Under the Microscope: 3 Biotech Stocks Pioneering Tomorrow’s Cures
Via InvestorPlace
3 Biotech Stocks With the Strongest Clinical Pipelines
Via InvestorPlace
Where Exelixis Stands With Analysts
Via Benzinga
Earnings Outlook For Exelixis
Via Benzinga
Is Exelixis Stock a Buy Now?
Via The Motley Fool
3 Promising Biotech Stocks Flying Under the Radar
Via InvestorPlace
Exelixis (EXEL) Q3 2023 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Exelixis Announces Third Quarter 2023 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
4 Dominant Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
Via The Motley Fool
Topics Stocks
Exposures US Equities
Global Cancer Vaccines Market Share Is Expected To Reach $19.27 Billion By 2030
Via FinancialNewsMedia
Why Exelixis Stock Is Trading Lower Today
Via Benzinga
Detailed Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2023
From Exelixis, Inc.
Via Business Wire
3 Under-the-Radar Biotech Stocks to Buy in 2023
Via The Motley Fool
Exelixis to Release Third Quarter 2023 Financial Results on Wednesday, November 1, 2023
From Exelixis, Inc.
Via Business Wire
14 Analysts Have This to Say About Exelixis
Via Benzinga
Don't overlook NASDAQ:EXEL—a stock with solid growth prospects and a reasonable valuation.
Via Chartmill
Steady Eddies: 3 Low Beta Stocks for Long-Haul Gains
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.